London Co. of Virginia Has $3.09 Million Holdings in Icon Plc $ICLR

London Co. of Virginia boosted its stake in shares of Icon Plc (NASDAQ:ICLR) by 93.5% in the 1st quarter, Holdings Channel.com reports. The firm owned 27,939 shares of the medical research company’s stock after buying an additional 13,501 shares during the quarter. London Co. of Virginia’s holdings in Icon were worth $3,092,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently bought and sold shares of the company. Toth Financial Advisory Corp bought a new stake in shares of Icon in the fourth quarter valued at about $27,000. EFG International AG bought a new position in Icon during the fourth quarter valued at about $27,000. Abound Financial LLC bought a new position in Icon during the fourth quarter valued at about $54,000. Johnson Financial Group Inc. acquired a new position in Icon in the 3rd quarter valued at approximately $71,000. Finally, Blue Trust Inc. raised its holdings in Icon by 207.5% in the 1st quarter. Blue Trust Inc. now owns 658 shares of the medical research company’s stock valued at $73,000 after acquiring an additional 444 shares in the last quarter. 95.61% of the stock is owned by institutional investors.

Icon Stock Performance

Icon stock opened at $165.76 on Monday. The company has a market cap of $12.69 billion, a PE ratio of 29.49, a PEG ratio of 8.14 and a beta of 1.22. The company has a current ratio of 1.14, a quick ratio of 1.14 and a debt-to-equity ratio of 0.31. Icon Plc has a 1 year low of $66.57 and a 1 year high of $203.91. The company’s 50-day moving average is $151.11 and its two-hundred day moving average is $136.00.

Wall Street Analyst Weigh In

ICLR has been the subject of a number of analyst reports. Weiss Ratings downgraded shares of Icon from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday, May 29th. Mizuho upped their target price on shares of Icon from $180.00 to $190.00 and gave the company an “outperform” rating in a research note on Friday, June 26th. Citigroup increased their price target on shares of Icon from $140.00 to $165.00 and gave the stock a “neutral” rating in a research report on Thursday, June 25th. JPMorgan Chase & Co. raised their price target on shares of Icon from $130.00 to $155.00 and gave the stock a “neutral” rating in a research note on Thursday, June 25th. Finally, Robert W. Baird raised their target price on Icon from $168.00 to $186.00 and gave the stock an “outperform” rating in a research report on Thursday, June 25th. Seven research analysts have rated the stock with a Buy rating, six have issued a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat, Icon currently has an average rating of “Hold” and an average target price of $168.73.

Icon Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.